Antisense & RNAi Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Global Antisense & RNAi Therapeutics Market is segmented by Therapeutics (RNA Interference and RNA Antisense), Route of Administration (Intravenous Route, Subcutaneous Route, Intrathecal Route, Pulmonary Delivery, Intraperitoneal Injection, and Others), Indication (Autosomal Recessive Disease, Autosomal Dominant Disease, Chromosomal Disease, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments.

Antisense & RNAi Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Antisense & RNAi Therapeutics Industry Overview

The antisense and RNAi therapeutics market is consolidated in nature due to the presence of a limited number of companies operating across the globe. The competitive landscape includes an analysis of a few international as well as local companies that operate in the market such as Alnylam Pharmaceuticals, Inc., Biogen Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Sarepta Therapeutics, Inc., Novartis AG, Silence Therapeutics, Arbutus Biopharma (Formerly Called Tekmira Pharmaceuticals), Isarna Therapeutics GmbH, Gene Signal International SA, Arrowhead Pharmaceuticals, Inc., and Benitec Biopharma Ltd, among others.

Antisense & RNAi Therapeutics Market Leaders

  1. Alnylam Pharmaceuticals, Inc.

  2. Biogen Inc.

  3. Ionis Pharmaceuticals (Akcea Therapeutics, Inc.)

  4. Sarepta Therapeutics, Inc.

  5. Novartis AG

  6. *Disclaimer: Major Players sorted in no particular order
Antisense and RNAi Therapeutics Market Concentration

Antisense & RNAi Therapeutics Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?